Successful private placement of new Biocartis shares for € 80 million

A continuous commitment to Life Science Companies

Biocartis, an innovative molecular diagnostics company, announced on November 28th (16:30CET) its intention to raise ca. € 60 million in a private placement through an accelerated book building, with the possibility to increase the size of the placement. The offering closed by 19:30CET on the same day.

Following strong demand and a significant oversubscription, it was decided to upsize the placement to € 80 million at a price of € 12.50 per share, implying a discount of 7.6% versus the prior day closing price or a mere 2.9% versus the prior month average price. The new shares were placed with ca. 75 Belgian, European and US institutional investors.

After having contributed to to the successful IPO and private placement of Biocartis in April 2015 and November 2016 respectively, Degroof Petercam also played a part in supporting Biocartis in this private placement.

Degroof Petercam is once more very pleased with the success of this transaction, which once again demonstrates its continuous commitment to life sciences companies.

​ ​

About Degroof Petercam

Degroof Petercam is a reference financial institution with a history dating back to 1871. As an independent group owned by family shareholders with a long term commitment, we serve private and institutional investors.

Our clients benefit from a unique combination of services in private banking, institutional asset management, investment banking (corporate finance and financial intermediation) and asset services. The total clients assets (under management, under administration and in custody)is close to 75 billion euro.

Headquartered in Brussels, we employ more than 1,400 professionals through offices in Belgium, Luxembourg, France, Switzerland, Spain, The Netherlands, Germany and Italy.

Degroof Petercam
Rue de l'Industrie | Nijverheidsstraat 44
1040 Brussels